CLOs on the Move

Better Therapeutics

www.bettertx.com

 
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bettertx.com
  • 548 Market Street #49404
    San Francisco, CA USA 94104
  • Phone: 415.887.2311

Executives

Name Title Contact Details

Similar Companies

A W Research Laboratories

A W Research Laboratories is a Brainerd, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tactical Therapeutics

Tactical Therapeutics is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nizhoni Health

At Nizhoni Health, we believe that quality of care and quality of staff go hand-in-hand. Our highly trained staff consists of qualified, experienced nurses and clinical specialists. Our nurses have worked in a variety of clinical settings including the major teaching hospitals within the metropolitan area. Nizhoni Health is a Medicare/Medicaid certified home health agency. Our enduring goal is to provide an effective alternative to inpatient hospitalization and assist clients in making the transition to the community. All clients are treated with dignity and respect.

BioCatalyst International

BioCatalyst International is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.